# Helicase Venture

> Helicase Venture is a VC fund in Boston backing Biotechnology and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 10
- Last investment: Jan 2022
- Lead investor: 10%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/helicase-venture/about/
- Website: https://www.helicaseventure.com/

Helicase Venture is an investment firm focused on healthcare. Through our industry experience and domain expertise, we work closely with our portfolio companies and entrepreneurs to navigate the challenges and to grow together with the right opportunities.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 70% |
| Health Care | 4 | 40% |
| Biopharma | 2 | 20% |
| Life Science | 2 | 20% |
| Therapeutics | 2 | 20% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 3 | 30% |
| Series A | 2 | 20% |
| Series B | 2 | 20% |
| Seed | 1 | 10% |
| Series C | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 60% |
| Taiwan | 1 | 10% |
| Austria | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ribbon Bio | Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis. | $20.2M | Series A | Jan 31, 2022 |  |
| Absci | Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $125M | Venture - Series Unknown | Mar 23, 2021 |  |
| Contineum Therapeutics | Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to thenervous system. | $80M | Series C | Feb 11, 2021 |  |
| Totient | Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble themost potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts. | $10M | Seed | Sep 10, 2020 |  |
| Totient | Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble themost potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts. | $10M | Seed | Sep 10, 2020 |  |
| Contineum Therapeutics | Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to thenervous system. | $32M | Series B | Dec 18, 2019 |  |
| Landos Biopharma | Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.The company's therapeutics are novel, locally-acting small molecules targeting inflammatory bowel disease (IBD), crohn's disease (CD) and ulcerative colitis (UC), enabling healthcare providers to cure their patients. | $60M | Series B | Aug 13, 2019 |  |
| X-Vax Technology | X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells willprovoke an entirely new and effective immune response – so that they can finally beat these pathogens.The company was founded in 2015 and based in Jupiter, Florida. | $56M | Series A | Jul 23, 2019 |  |
| Tangible Science | Tangible Science is a developer of contact lenses designed to reduce lens discomfort in dry eye diseases.The company's lenses use polymer-based coating technology that creates a bio-compatible and highly hydrated surface which prevents disruption of the natural tear film, enabling users to eliminate dry eye symptoms. | $2M | Venture - Series Unknown | Jan 15, 2019 |  |
| Medeon Biodesign | Medeon Biodesign (TPEx: 6499) is a publicly traded company located in Taipei, Taiwan, and currently listed on Taipei Exchange. The company focuses on the development of medical devices for minimally invasive surgeries to treat diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity,gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery |  | Venture - Series Unknown | Jan 01, 2019 |  |

10 of 10 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 4 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 4 deals together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 3 deals together
- [Brace Pharma](https://shizune.co/investors/profile/brace-pharma) — VC Fund, 3 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 3 deals together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Helicase Venture invest in?

Helicase Venture invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Venture - Series Unknown and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Helicase Venture last invest?

The most recent investment recorded for Helicase Venture closed in Jan 2022. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co